Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?

Journal of Endocrinological Investigation

Volumn 26, Issue 7, 2003, Pages 655-659

  Bahceci, M ^a   Tuzcu, A ^a   Bahceci, S ^a   Tuzcu, S ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Free androgen index; HOMA; Insulin resistance; Polycystic ovary syndrome; Prolactin

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CHOLESTEROL; ESTRADIOL; FAT; FOLLITROPIN; GLUCOSE; GONADOTROPIN DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; HYDROXYPROGESTERONE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; THYROTROPIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANDROGEN BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; CELL FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERPROLACTINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PROLACTIN BLOOD LEVEL; STATISTICAL ANALYSIS;

EID: 0142088910     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347025     Document Type: Article

References (20)

1. Legro RS, Dunaif A. The role of insulin resistance in polycystic ovary syndrome. The Endocrinologist 1996, 6: 307.
2. Dunaif A. Insulin resistance and polycystic ovary syndrome: Mechanisms and implications for pathogenesis. Endocr Rev 1997, 18: 774-800.
3. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980, 50: 113-6.
4. Givens JR, Kerber IJ, Wiser WL, Andersen RN, Coleman SA, Fish SA. Remission of acanthosis nigricans associated with polycystic ovarian disease and a stromal luteoma. J Clin Endocrinol Metab 1974, 38: 347-55.
5. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995, 44: 525-31.
6. Futterweit W. Pathologic anatomy of polycystic ovarian disease. In: Futterweit W ed. Polycystic ovarian disease. New York: Springer Verlag 1984, 41-2.
7. Reis FM, Reis AM, Coimbra CC. Effects of hyperprolactinemia on glucose tolerance and insulin release in male and female rats. J Endocrinol 1997, 153: 423-8.
8. Matsuda M, Mori T. Effect of estrogen on hyperprolactinemia-induced glucose intolerance in SHN mice. Proc Soc Exp Biol Med 1996, 212: 243-7.
9. Serri O, Beauregard H, Rasio E, Hardy J. Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 1986, 45: 572-4.
10. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 2003 26: 341-6.
11. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84: 165-9.
12. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998, 83: 2694-8.
13. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84: 3666-72.
14. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21: 1440-7.
15. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: Implications, etiology, and management. Am J Obstet Gynecol 1981, 140: 815-30.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
17. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983, 57: 356-9.
18. Toprak S, Yonem A, Cakir B, et al. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res 2001, 55: 65-70.
19. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: A novel approach to the treatment of Type 2 diabetes. Diabetes Care 2000, 23: 1154-61.
20. Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985, 28: 138-42.